7 results about "Neutral fat" patented technology

To provide a novel material or composition that is effective in preventing or alleviating dyslipidemia. [Solution] A material or composition containing live or dead yeast cells or yeast hydrolysates for preventing or alleviating dyslipidemia. Dyslipidemia here refers to one or more abnormalities in blood concentrations of LDL cholesterol (bad cholesterol), HDL cholesterol (good cholesterol), and triglycerides (neutral fats). Zygosaccharomyces rouxii or Pichia are preferred as the yeast. The yeast is preferably of food origin and preferably intended for human consumption.

The invention belongs to the field of medicines, and relates to application of nikkomycin in preparation of a medicine for treating lipid deposition myopathy. The invention discloses application of nikkomycin to treatment of lipid deposition myopathy, in particular to treatment of simple myopathy type neutral fat deposition caused by PNPLA2 gene mutation. The simple myopathy type neutral fat deposition disease is autosomal recessive inheritance progressive aggravated lipid deposition myopathy and involving multiple systems of the whole body, no treatment means exists at present, and a patient has fatal symptoms such as whole body myasthenia and cardiomyopathy in the late period. It is found that nikkomycin can remarkably reverse lipid droplet deposition in fibroblasts of a patient suffering from the simple myopathy type neutral fat deposition disease, relieve inflammatory response, improve autophagy hindering and increase energy generation, and nikkomycin can serve as an effective component for treating the disease. The composition has a definite application prospect in patients with simple myopathy type neutral fat deposition disease which are not treated by medicines.

To provide a new compound useful for promoting the decomposition of neutral fat in fat cells, and to provide a new therapeutic agent for obesity and a new therapeutic agent for obesity-related diseases, each containing the compound as an active ingredient.SOLUTION: There are provided a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a therapeutic agent for obesity and a therapeutic agent for obesity-related diseases comprising the same as an active ingredient. (wherein, X and Z represent N or C, R1 represents alkyl or the like, R2 and R3 represent hydrogen, alkoxycarbonyl, alkylcarbamoyl or the like, R4 and R7 represent hydrogen, R5 and R6 represent hydrogen, alkoxycarbonyl, alkylcarbamoyl or the like) SELECTED DRAWING: Figure 1

The application relates to application of a substituted benzamide in preparation of a medicine for preventing or treating non-alcoholic fatty liver, characterized in that the benzamide structural formula is shown in formula 1: formula 1, wherein R1, R2 and R3 are the same or different and are selected from one of C1-C4 alkyl groups. The substituted benzamide, especially NGI-1, significantly improves the pathological characteristics of non-alcoholic fatty liver disease, significantly alleviates liver steatosis, reduces neutral fat deposition, improves hepatocyte structure and reduces mild liver fibrosis in a KIF13B MKO mouse model fed with CDAHFD, and indicates that the substituted benzamide, especially NGI-1, has a good effect in the treatment of non-alcoholic fatty liver (NAFLD). The application first proposes that the substituted benzamide, especially NGI-1, has potential application value in the treatment of NAFLD, and provides a new strategy and a candidate drug for early intervention of non-alcoholic fatty liver.

The invention relates to an application of substituted benzamide in preparation of a medicine for preventing or treating non-alcoholic fatty liver disease, which is characterized in that the benzamide has a structural formula as shown in a formula 1, and R1, R2 and R3 in the formula 1 are the same or different and are selected from one of C1-C4 alkyl groups. Substituted benzamide, especially NGI-1, can significantly improve the pathological characteristics of the non-alcoholic fatty liver disease, and in a KIF13B MKO mouse model fed by CDAHFD, can significantly alleviate liver fatty degeneration, reduce neutral fat deposition, improve liver cell structure, and alleviate mild hepatic fibrosis, indicating that the substituted benzamide has a good effect in the treatment of the non-alcoholic fatty liver disease (NAFLD). The invention proposes that substituted benzamide, especially NGI-1, has a potential application value in treatment of NAFLD for the first time, and provides a new strategy and a candidate drug for early intervention of the non-alcoholic fatty liver disease.

The present application relates to sunflower peptide preparation technical field, disclose a kind of sunflower peptide preparation method and application of anti-oxidation and delaying senility function, the preparation method is removed neutral fat and phospholipid in turn by stage enzyme method defatting, then the active peptide segment rich in tyrosine, phenylalanine in sunflower protein is cut directionally by using double-targeted engineering enzyme synergistic hydrolysis, active peptide is efficiently separated by temperature response and charge screening using temperature-sensitive copolymer intelligent purification, finally the stabilization of active peptide is realized by biological enzymatic crosslinking.The sunflower peptide is used for preparing oral preparation, medical dressing or transdermal absorption cosmetics of anti-oxidation and delaying senility. By double-targeted engineering enzyme synergistic cutting, the anti-oxidation group is accurately retained, and the invalid peptide segment is reduced;Stage defatting combined with temperature-sensitive purification realizes efficient enrichment of active peptide;Biological crosslinking self-assembly technology replaces chemical crosslinking, which eliminates toxic residues while ensuring stability, and experiments prove that the application has the effect of anti-oxidation and delaying senility.

The present invention relates to a pharmaceutical composition for preventing or treating obesity, said pharmaceutical composition containing a GLP (Glucagon Like Peptide) analogue as an active ingredient. The GLP analogue of the present invention has been confirmed to be an analogue of GLP-1 and GLP-2, which has been confirmed to have a long in-vivo activity duration due to an increase in the half-life thereof, thereby having an excellent effect in the prevention or treatment of metabolic diseases. Specifically, the peptide disclosed by the invention not only can reduce the weight and fat of an individual, reduce blood sugar, total cholesterol in blood, high-density lipoprotein, low-density lipoprotein and fat factor level in the blood of neutral fat, but also can reduce ASL and AST levels of the liver, the weight of the liver, the degree of hepatic fatty disease and the level of the neutral fat of the liver. From this point, the peptide according to the present invention can be used as an excellent preventive or therapeutic agent for metabolic diseases.